(Reuters) - The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy.
via Reuters: Health News Read More Here..
No comments:
Post a Comment